Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation - September 13, 2022

OIS Glaucoma Innovation Summit

OIS Retina Innovation Showcase

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
Webinar to be held Friday, September 23, 2022   @   10 a.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced
View HTML
Toggle Summary Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770
View HTML
Toggle Summary Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 15, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million , up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022   Aerie Expects to be Cash Flow Break Even During 2024 DURHAM, N.C.DURHAM ,
View HTML
TOP